American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Aldeyra Therapeutics, Inc. (ALDX)

$0.65 +0.68% NASDAQ: ALDX · 15-min delayed

LEXINGTON, Massachusetts
Public · NASDAQ: ALDX
7 employees

Visit website Follow

$91.7MMarket cap

-$33.8MNet income

7Employees

ALDXNASDAQ

2014IPO

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: ALDX
Employees: 7
IPO date: May 2, 2014
Headquarters: 131 HARTWELL AVENUE
LEXINGTON, Massachusetts 02421
Phone: 781-761-4904
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 529900HGKY864E4Y9014

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: ALDX Nasdaq
SEC CIK: 1341235
LEI: 529900HGKY864E4Y9014
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Aldeyra Therapeutics, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/aldeyra-therapeutics-inc/"><img src="https://americancompanies.com/badge/aldeyra-therapeutics-inc.svg" alt="Aldeyra Therapeutics, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Aldeyra Therapeutics, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Net income: -$33.8M
Total assets: $72.1M
Market cap: $91.7M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: ALDX

$0.65 +0.68%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.65 $5.74

52-week range

Market cap: $91.7M
Shares outstanding: 141.1M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: May 2, 2014

Aldeyra Therapeutics, Inc. (ALDX) Stock Price

Reported a net loss of $33.8M.
Trading 89% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Aldeyra Therapeutics, Inc..

Write a review

Newsroom

News about Aldeyra Therapeutics, Inc.

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week Zacks Investment Research · 2026-10-15 · neutral Here's Why You Should Add ANRO Stock to Your Portfolio Now Zacks Investment Research · 2026-10-14 · negative Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal Zacks Investment Research · 2026-10-14 · neutral Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why Zacks Investment Research · 2026-10-12 · neutral PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know Zacks Investment Research · 2026-10-12 · neutral argenx Meets Primary Endpoint in Phase II Celiac Disease Study Zacks Investment Research · 2026-10-09 · neutral

News & sentiment via Polygon.io

FAQ

Aldeyra Therapeutics, Inc.: frequently asked questions

Is Aldeyra Therapeutics, Inc. an American company?

Aldeyra Therapeutics, Inc. is a US-based company headquartered in Lexington, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Aldeyra Therapeutics, Inc. headquartered?

Aldeyra Therapeutics, Inc. is headquartered in Lexington, Massachusetts, United States.

Is Aldeyra Therapeutics, Inc. publicly traded?

Yes — Aldeyra Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol ALDX on the NASDAQ.

What does Aldeyra Therapeutics, Inc. do?

Aldeyra Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore